CAJ | 학술논문

目的：检测EBI3、p35在鼻咽癌(NPC)组织中的表达水平，分析EBI3和p35在NPC发生发展中的作用及临床意义。方法应用免疫组织化学方法检测50例NPC患者、30例癌旁黏膜和25例鼻咽黏膜慢性炎患者炎症组织中EBI3和p35表达，并分析其与NPC患者临床分期、病理组织类型和淋巴结转移的关系。结果 NPC组织中EBI3高表达率为62.0%，显著高于癌旁黏膜组织中的36.7%(χ2=4.83，P<0.05)和鼻咽黏膜慢性炎患者炎症组织中的36.0%(χ2=4.53，P<0.05)。T3~T4期NPC患者中EBI3高表达率显著高于T1~T2期患者(χ2=17.24，P<0.01)；非角化型鳞癌NPC患者癌组织中EBI3高表达率显著高于角化型鳞癌患者(χ2=8.78，P<0.01)；有颈部淋巴结转移NPC患者癌组织中EBI3高表达率显著高于无颈部淋巴结转移癌患者(χ2=14.49，P<0.01)。p35高表达率为60.0%，显著高于癌旁黏膜组织中的33.3%(χ2=5.33，P<0.05)和鼻咽黏膜慢性炎患者炎症组织中的36.0%(χ2=3.85，P<0.05)。T3~T4期NPC患者中p35高表达率显著高于T1~T2期患者(χ2=19.28，P<0.01)；非角化型鳞癌NPC患者癌组织中p35高表达率显著高于角化型鳞癌患者(χ2=7.24，P<0.01)；有颈部淋巴结转移NPC患者癌组织中p35高表达率显著高于无颈部淋巴结转移癌患者(χ2=5.56，P<0.05)。NPC组织中EBI3和p35表达之间呈正相关(r=0.328，P<0.05)。结论 NPC组织中EBI3和p35高表达与鼻咽癌发生、发展相关，有望作为患者预后判断的重要标志物。
목적：검측EBI3、p35재비인암(NPC)조직중적표체수평，분석EBI3화p35재NPC발생발전중적작용급림상의의。방법응용면역조직화학방법검측50례NPC환자、30례암방점막화25례비인점막만성염환자염증조직중EBI3화p35표체，병분석기여NPC환자림상분기、병리조직류형화림파결전이적관계。결과 NPC조직중EBI3고표체솔위62.0%，현저고우암방점막조직중적36.7%(χ2=4.83，P<0.05)화비인점막만성염환자염증조직중적36.0%(χ2=4.53，P<0.05)。T3~T4기NPC환자중EBI3고표체솔현저고우T1~T2기환자(χ2=17.24，P<0.01)；비각화형린암NPC환자암조직중EBI3고표체솔현저고우각화형린암환자(χ2=8.78，P<0.01)；유경부림파결전이NPC환자암조직중EBI3고표체솔현저고우무경부림파결전이암환자(χ2=14.49，P<0.01)。p35고표체솔위60.0%，현저고우암방점막조직중적33.3%(χ2=5.33，P<0.05)화비인점막만성염환자염증조직중적36.0%(χ2=3.85，P<0.05)。T3~T4기NPC환자중p35고표체솔현저고우T1~T2기환자(χ2=19.28，P<0.01)；비각화형린암NPC환자암조직중p35고표체솔현저고우각화형린암환자(χ2=7.24，P<0.01)；유경부림파결전이NPC환자암조직중p35고표체솔현저고우무경부림파결전이암환자(χ2=5.56，P<0.05)。NPC조직중EBI3화p35표체지간정정상관(r=0.328，P<0.05)。결론 NPC조직중EBI3화p35고표체여비인암발생、발전상관，유망작위환자예후판단적중요표지물。
Objective To detect the expression of EBI3 and p35 in nasopharyngeal carcinoma (NPC) and to analyze the clinical significance of them in NPC patients. Methods Immunohistochemistry was used to detect 50 cases of NPC patients, 30 cases of adjacent mucosa tissues and 25 cases of nasopharyngeal mucosa chronic inflamma-tory patients. The relationship of EBI3 or p35 with clinical stage, pathological type and lymph node metastasis were al-so analyzed on 50 cases of NPC patients. Results The high expression rates of EBI3 in NPC patients was significant-ly higher than those in adjacent mucosa (62.0%to 36.7%,χ2=4.83, P<0.05) and nasopharyngeal mucosa chronic in-flammatory tissue (62.0%to 36.0%,χ2=4.53, P<0.05). The high expression rates of EBI3 in stage T3~T4 NPC patients were significantly higher than those in stage T1~T2 NPC patients (χ2=17.24, P<0.01). The high expression rates of EBI3 in non-keratinizing squamous carcinoma patients was significantly higher than those in keratinizing squamous carcinoma patients (χ2=8.78, P<0.01), and in NPC patients having a cervical lymph node metastasis than those with-out lymph node metastasis (χ2=14.49, P<0.01). In NPC patients cancer tissues, we also found the high expression rates of p35 were significantly higher than those in adjacent mucosa (60.0%to 33.3%,χ2=5.3, P<0.05) and nasopharyn-geal mucosa chronic inflammatory tissue (60.0%to 36.0%,χ2=3.85, P<0.05). The high expression rates of p35 on stage T3~T4 NPC patients were significantly higher than those on stage T1~T2 NPC patients (χ2=19.28, P<0.01), in non-kera-tinizing squamous carcinoma patients than those in keratinizing squamous carcinoma patients (χ2=7.24, P<0.01), and in NPC patients having a cervical lymph node metastasis than those without lymph node metastasis (χ2=5.56, P<0.05). The expression of EBI3 in NPC patients was positively related to the expression of p35 (r=0.328, P<0.05). Conclusion The high expression of EBI3 and p35 in NPC patients may relevant to tumor pathogenesis and progres-sion, and maybe an important marker for NPC prognosis.